Substituted piperidines
View Patent ↗A novel class of substituted piperidines, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.
1. A method for treating overweight or obesity, comprising:
administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (I):
wherein
m is 1,
R 1 is
C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl,
which may optionally be substituted with one or more substituents selected from halogen, C 1-6 -alkoxy and hydroxy,
C 3-8 -cycloalkyl, C 5-8 -cycloalkenyl, C 3-8 -cycloalkyl-C 1-6 -alkyl, di(C 3-8 -cycloalkyl)-C 1-6 -alkyl, C 3-8 -cycloalkyl-C 2-6 -alkenyl, C 3-8 -cycloalkyl-C 2-6 -alkynyl, C 5-8 -cycloalkenyl-C 1-6 -alkyl, C 5-8 -cycloalkenyl-C 2-6 -alkenyl, C 5-8 -cycloalkenyl-C 2-6 -alkynyl,
wherein the cyclic moieties may optionally be substituted with one or more substituents selected from C 1-6 -alkyl, halogen, trifluoromethyl and 2,2,2-trifluoroethyl,
R 2 is C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-8 -cycloalkyl or C 3-8 -cycloalkyl-C 1-6 -alkyl,
X is —CH 2 —(CH 2 ) n —, —(CH 2 ) n —CH═CH—(CH 2 ) p —, —CH 2 —(CH 2 ) n —O—(CH 2 ) p —, —CH 2 —(CH 2 ) n —C(═O)—(CH 2 ) p —, —CH 2 —(CH 2 ) n —S—(CH 2 ) p —, —CH 2 —(CH 2 ) n —S(═O)—(CH 2 ) p — or —CH 2 —(CH 2 ) n —S(═O) 2 —(CH 2 ) p —,
n and p are independently 0, 1, 2, 3 or 4,
R 3 and R 4 are independently hydrogen, methyl or trifluoromethyl,
Y is
(a) phenyl, naphthyl, pyridyl, benzoxazolyl or benzothiophenyl, which may optionally be substituted with one or more substituents selected from
halogen, nitro, cyano, hydroxy, oxo, C 1-7 -alkanoyl, C 1-6 -alkylthio, C 1-6 -alkylsulfonyl, C 1-6 -alkyl, C 1-6 -alkoxy, C 3-8 -cycloalkyl, trifluoromethyl, trifluoromethoxy, —NR 5 R 6 and —O(C═O)NR 5 R 6 ,
wherein R 5 and R 6 independently are hydrogen, C 1-6 -alkyl, C 3-8 -cycloalkyl, C 1-7 -alkanoyl or aryl, or R 5 and R 6 together with the nitrogen atom to which they are attached form a 4 to 7 membered, saturated or unsaturated ring,
or wherein two substituents in adjacent positions form a radical —O—(CH 2 ) 1-3 —O—,
phenyl, phenoxy, phenyl-C 1-6 -alkyl and phenyl-C 1-6 -alkoxy, wherein the ring moieties optionally may be substituted with one or more substituents selected from
halogen, nitro, cyano, hydroxy, C 1-7 -alkanoyl, C 1-6 -alkylthio, C 1-6 -alkylsulfonyl, C 1-6 -alkyl, C 1-6 -alkoxy, C 3-8 -cycloalkyl, trifluoromethyl, trifluoromethoxy, —NR 7 R 8 and —O(C═O)NR 7 R 8 ,
wherein R 7 and R 8 independently are hydrogen, C 1-6 -alkyl, C 3-8 -cycloalkyl, C 1-7 -alkanoyl or aryl, or R 7 and R 8 together with the nitrogen atom to which they are attached form a 4 to 7 membered, saturated or unsaturated ring,
or wherein two substituents in adjacent positions form a radical —O—(CH 2 ) 1-3 —O—
(b) C 3-8 -cycloalkyl, which may optionally be substituted with one or more substituents selected from
C 1-6 -alkyl, C 1-6 -alkoxy, C 1-6 -alkylthio, cyano, trifluoromethyl, trifluoromethoxy and halogen,
as well as any diastereomer or enantiomer or tautomeric form thereof, mixtures of these or a pharmaceutically acceptable salt thereof.
2. A method according to claim 1 , wherein the therapeutically effective amount of the compound is in the range of from about 0.05 mg to about 2000 mg per day.
3. A method according to claim 1 , wherein the therapeutically effective amount of the compound is in the range of from about 0.1 mg to about 1000 mg per day.
4. A method according to claim 1 , wherein the therapeutically effective amount of the compound is in the range of from about 0.5 mg to about 500 mg per day.